Scientific topics
Keywords
ITMO
Laura Fouassier PhD physiologie & Physiopathology, Sorbonne Université
Course and current status
Current position :
I joined the NABI (Nanomedicine, Extracellular Biology, Integratome, and Health Innovations) lab (https://nabi.u-paris-sciences.fr/fr/accueil/), led by Dr. Florence Gazeau, on July 2, 2025, as Deputy Unit Director and Head of an emerging research team.
My research focuses on biomedical science, with a particular emphasis on the development of clinical twins in oncology—3D experimental models derived from patient samples. I also study the tumor microenvironment, including both fibrotic and immune components, and work on the development of innovative, physics-based cancer therapies https://laurafouassier14.wixsite.com/fouassierlab.
This research is highly interdisciplinary and carried out in close collaboration with physicists, chemists, clinicians, pathologists, surgeons, and endoscopists.
Degrees
- Master’s Degree in Molecular & Cellular pathophysiology (Sorbonne Université, 2008)
- PhD in Physiology & Pathophysiology (Sorbonne Université, 1998)
- Research Direction Habilitation (HDR) (Univ. Paris Cité, 2008)
- University Diploma (DU) "Ethical animal experimentation and welfare, level 1" (Sorbonne Université, Paris, 2009)
Scientific summary
Previous position (-> july 2025)
- Research scientist (CRCN), team " Biliary and Fatty Liver Diseases ", Group leader “Hepatobiliary cancers”, Centre de Recherche Saint-Antoine (CRSA), Paris, France
Training and previous position
- PhD student, Saint-Antoine Hospital (Sorbonne Université, 1995-1998)
- Postdoc Department of Medicine, University of Colorado Health Sciences Center, Denver, USA (1999-2001)
- Junior researcher, CRSA (2001-2004)
Teaching & Mentorship
- Teaching module “BCPP spécialité épithéliums: structure d’interface (ESI)”, Université Paris-Cité, Master 2
- Mentoring program for PhD Students, Sorbonne Université
- Direction of 25 Master Students, 6 PhD students and 5 Postdoc (Since 2008)
Expertise
- Appointed member of the scientific committee of the ICAN BioCell Human Liver Biology Platform (Since 2025) https://ihuican.org/les-plateformes-scientifiques/ican-biocell-human-liver-biology/
- Appointed member of the Local Scientific Council (LSC) of the “UFR des Sciences Fondamentales et Biomédicales”, UPCité (Since 2025) https://biomedicale.u-paris.fr/instances-de-lufr/
- Member of the Editorial Board of Livers (Since 2021) https://www.mdpi.com/journal/livers/editors?search=fouassier
- Member of the Scientific Council of the DIM BioConvS (Since 2023) https://bioconvs.org/team/
- Member of 2 eCOST action (2023): Therapeutical applications of Cold Plasmas (PlasTHER CA20114) https://www.plasther.eu/fr-inserm/ and Precision medicine in biliary tract cancer (precision-BTC-Network CA22125) https://precision-btc.eu/members/?wg=&q=fouassier
- Member of the: “European Network for the Study of Cholangiocarcinoma” (ENS-CCA) (since 2015) https://eurocholangionet.eu/about-us/
- Member of the administrative board of the French Association pour l’étude des cancers et des affections des voies biliaires (ACABi) (since 2018) https://www.cancer-voies-biliaires.fr/accueil-acabi/
- Grant peer reviewer
- Journal peer reviewer
- PhD thesis evaluator
Distinctions
- Individual bonus RIPEC C3 (2023-25)
- Winner of a tenure position at Inserm (2004)
- Recipient of a post-doctoral fellowship from the ARC Foundation (2001-2002)
- Award recipient of an Inserm Foreign Fellowship (1999)
- Award recipient of the "Louis Forest-Siguret Mansuy" scholarship from the Chancellerie des Universités de Paris (1997)
- Award recipient of a grant from the pharmaceutical company Ferring (1996)
Patents
- Outil pour dispositif de traitement médical par plasma et dispositif correspondant
Inventeurs: T. Dufour, L. Fouassier, M. Camus, H. Decauchy.
Application number: WO2022229515 - Date of receipt: 03/11/2022 - N° of application: PCT/FR2021000041 - Date of publication of application: 28/04/2021 - Priority number: PCT/FR2021000041 - Priority date: 28/04/2021 - Classification CIB: A61B 18/04 - Classification CPC: A61B 18/042 - Patent family: WO2022229515A1.
Lien : https://data.inpi.fr/brevets/WO2022229515 - Medical device for applying a plasma jet (Dispositif medical pour application de plasma)
Inventeurs : T. Dufour, L Fouassier, F Judée, S Pledel, J Vaquero
N° of the application: WO2020254430 - Date of publication of the application: 24/12/2020 - Type of application: A1 - Filling number: PCT/EP2020066802 - Filling date: 17/06/2020 - Priority number: PCT/IB2019000782 - Priority date: 17/06/2019
Lien : https://data.inpi.fr/brevets/WO2020254430
Grants
2024-2028 European Commission, EIC Pathfinder
A minimally Invasive surgical platform aGainst paNcreatIc and biliary Tract cancErs using cold atmospheric PLASMA (IgnitePLASMA) (Co-PI, PI of the French Team) https://igniteplasma.eu/ and https://sante.sorbonne-universite.fr/actualites/projet-eic-pathfinder-igniteplasma
2024 Institut Polytechnique de Paris, programme prématuration
Cathéter à plasma froid pour le traitement endoscopique des tumeurs solides (CATHAPLAS) (Co-PI)
2024 Fondation de la Recherche Médicale, Programme prématuration
Cold atmospheric plasma to reduce stiffness of cholangiocarcinoma microenvironment to enhance immunotherapy efficiency (CAPSTIFF) (PI)
2024-2025 Ligue contre le Cancer. Dissecting the cholangiocarcinoma microenvironment to overcome resistance to immunotherapies (DROP-IN) (PI)
2024-2026 Fondation de France, postdoc grant Mirko Minini
DROP-IN: Dissecting the cholangiocarcinoma microenvironment to overcome resistance to immunotherapies (PI)
2024-2026 INCa PLBio. Prognostic, predictive and therapeutic interest of cholangiocarcinoma lymphocytic contexture (Co-PI)
2024-2026 Interdisciplinary approaches to oncogenic processes and therapeutic perspectives: Contributions to oncology of physics, chemistry and engineering sciences (PCSI), Aviesan ITMO Cancer-INSERM. Cold plasma-triggered anti-tumor immunotherapy, endoscopically applied to solid tumors of the digestive and respiratory tracts (PIONEERS) (Co-PI)
2023-2025 High Risk - High Gain, Research on cancers with poor prognosis, INCa.
Cold plasma-triggered anti-tumor immunotherapy, endoscopically applied to solid tumors of the respiratory and digestive tracts (PATHFINDERS) (Co-PI)
2022-2024 Interdisciplinary approaches to oncogenic processes and therapeutic perspectives: Contributions to oncology of physics, chemistry and engineering sciences (PCSI), Aviesan ITMO Cancer-INSERM.
TITRE: Targeting cholangiocarcinoma microenvironment by nanohyperthermia to reduce stiffness and promotes immunotherapy strategies (REVERSTIFF) (PI)
